Company Spotlight: Methinks CTA Stroke - Triage AI for Faster Interventions

We unpack the FDA 510(k) summary for Methinks CTA Stroke, an AI triage tool cleared to detect large vessel occlusions on CT angiograms. We explore its performance data, the addition of MCA-M2 vessel detection compared to its predicate device, and what its false positive rates mean for hospital procurement.

Key points

• Methinks CTA Stroke is a Class II triage and notification software that flags suspected large vessel occlusions (LVOs) in an average of 3.30 minutes.
• The FDA clearance is based on substantial equivalence to a predicate device, Viz.AI's ContaCT, but adds the ability to analyze the MCA-M2 vessel segment.
• In a retrospective study of 336 cases, the algorithm achieved 98.2% sensitivity and 91.6% specificity overall.
• Specificity dropped in older patients (over 70 years) and in cases with non-LVO conditions like severe stenosis or other acute ischemic events.
• The software is explicitly not for diagnostic use; it runs in parallel to the standard of care workflow to notify specialists for prioritized review.

Source: FDA 510(k) summary K251590: Methinks CTA Stroke (Methinks Software S.L) - U.S. Food and Drug Administration, 2025

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Methinks Software S.L · Product: Methinks CTA Stroke · FDA 510(k) K251590

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-methinks-cta-stroke-triage-ai-for-faster-interventio-1a4d38